Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00661_DB01319_nanopub.RAbJ5c9GUbIMos1V4lsD1kTTvTtGBL3WcADeQr6v5oS24#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00661_DB01319 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB01319 label "DDI between Verapamil and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB01319]" assertion.
- drugbank_resource:DB00661_DB01319 identifier "drugbank_resource:DB00661_DB01319" assertion.
- drugbank_resource:DB00661_DB01319 title "DDI between Verapamil and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed." assertion.
- drugbank:DB01319 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01319 assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01319 assertion.